The products are being advertised as more affordable alternatives to blockbuster weight-loss drugs. Here’s what doctors think ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

Dr. Patricia Brubaker and Dr. Pieter Cohen are the speakers at this year’s Trottier Public Science Symposium, Monday at 7 p.m. at McGill University’s Leacock Building, Room 132. Admission is free, but ...

Novo Nordisk (NVO) stock is falling Friday morning after the pharmaceutical giant shared that additional weight loss tied to higher doses of its oral drug was "limited" in its latest trial results.

Severe obesity is already a significant problem for many children, especially since obese children often become obese adults. Could the now popular weight-loss injection drugs be a solution for those ...

Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity.